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Abstract  
The aim of the study was to estimate the influence of interactions between peroxisome proliferator-activated receptor γ 
(PPARγ) and target genes lipoprotein lipase (LPL), interleukin 6 (IL6), angiotensin converting enzyme (ACE), and 
angiotensin II type 1 receptor (AT1R) on metabolic syndrome (MetSy) and its traits. 
Methods: The study included 527 participants (263 with MetSy and 264 controls). Genotyping of PPARγ Pro12Ala, 
LPL PvuII (-/+), IL6 -174G>C, ACE I/D and AT1R 1166A>C was performed using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) based methods.  
Results: Interaction between PPARγ Pro12Ala and LPL (Pvu-/+) improved prediction of MetSy over and above 
prediction based on a model containing no interactions (χ2=7.22; df=1; p=0.007). In the group of participants with 
PPARγ Pro12Ala or Ala12Ala genotypes, those with LPL Pvu (-/+) or (+/+) genotype had greater odds for MetSy 
(OR=5.98; 95% CI: 1.46-24.47, p=0.013). Interaction between PPARγ Pro12Ala and IL6 -174G>C improved prediction 
of high fasting blood glucose (χ2=13.99; df=1; p<0.001). PPARγ Ala12 variant was found protective in patients with IL6 
-174GG genotype (OR=0.10; 95% CI: 0.02-0.57, p=0.01), while in the case of IL6 -174C allele carriers, for PPARγ 
Ala12 carriers larger odds for high glucose levels compared with Pro12 variant were observed (OR=2.39; 95% CI: 1.11-
5.17, p=0.026). Interactions of PPARγ and ACE were significant for BMI. In the group with ACE DD genotype, those 
with PPARγ Pro12Ala or Ala12Ala genotype have greater odds for obesity (OR=9.98; 95% CI: 1.18-84.14, p=0.034). 
Conclusions: PPARγ gene variants can, in interaction with some of its target genes, modulate physiological processes 
leading to the development of MetSy.  
 
Key words: Metabolic syndrome, Genetic polymorphisms, Peroxisome proliferator-activated receptor γ gene, 
Lipoprotein lipase, Interleukin 6, Angiotensin converting enzyme, Angiotensin II type 1 receptor 
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INTRODUCTION 
The pathogenesis of metabolic syndrome (MetSy) has been associated with the effect of genetic predisposition in 
combination with environmental factors (Lusis et al. 2008; Lin et al., 2005). Whereas the importance of genetic factors 
for the development of MetSy has been widely recognized, the contribution of genes has not yet been fully clarified. 
Many association studies have been conducted with inconsistent results (Monda et al., 2010; Park et al. 2009). 
Considering the central role of adipose tissue in MetSy, different adipocyte-related genes have been studied as possible 
candidates in MetSy, including peroxisome proliferator-activated receptor γ (PPARγ), lipoprotein lipase (LPL), renin-
angiotensin system (RAS)-related genes - angiotensin converting enzyme (ACE) and angiotensin II type 1 receptor 
(AT1R), and interleukin 6 (IL6), which exhibit considerable variability.  
PPARs are transcription factors implicated in different biological pathways ranging from lipid and glucose homeostasis 
and insulin sensitization, to control of cell proliferation/differentiation, inflammation, and immunity (Sharma and 
Staels, 2007; Olefsky, 2000). Endogenous ligands are thought to bind PPARγ and promote downstream gene target 
transcription (Ide et al., 2003; Bell-Parikh et al., 2003). Because of alternative mRNA splicing, two protein isoforms 
occur: PPARγ1 and PPARγ2. While PPARγ1 is found ubiquitously in the body, PPARγ2 is largely found in adipose 
tissue. Studies have demonstrated that PPARγ has a critical role in regulating adipocyte differentiation and lipid 
accumulation (Rangwala and Lazar, 2009). The PPARγ Pro12Ala variant (rs1801282) has been found to modulate 
transcriptional activity and has a reduced affinity for the response element in target genes, which leads to the less 
efficient stimulation of PPARγ target genes (He, 2009). The frequency of the 12Ala allele ranges from 2% to 18% in 
healthy people (Paracchini et al., 2005). PPARγ function is a key factor in mediating conditions such as dyslipidemia, 
obesity, and insulin resistance (Huang et al., 2011; Gouda et al., 2010), and has also been implicated in the development 
of cardiovascular diseases (Azhar, 2010).  
LPL plays the major role in the metabolism and transport of lipids. Distinct physiological activities of LPL together 
regulate the supply of fatty acids to various tissues for either storage or oxidation. Insulin has a major effect on LPL 
activity in adipose tissue during adipocyte differentiation by increasing LPL gene transcription (Semenkovich et al., 
1989). Glucose also increases adipose tissue LPL activity. Several mutation loci have been detected in LPL gene and 
investigated for their associations with plasma lipid level and the development of cardiovascular diseases 
(Angelakopoulou et al., 2012). Polymorphism LPL PvuII (-/+) (rs285) is caused by the absence (-) or presence (+) of a 
C>T transition at position 497 in intron 6, and may interfere with correct splicing of mRNA, diminishing the enzyme 
activity. 
Interleukin 6 (IL6) is a pleiotropic inflammatory cytokine derived from diverse tissues. In chronic inflammation it has 
rather proinflammatory properties. There is evidence that variations in IL6 gene are associated with cytokine and 
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metabolic modulation, leading to impaired glucose and lipid homeostasis and increasing cardiometabolic risk (Stephens 
et al., 2004). Polymorphism -174G>C (rs1800795) is most prevalent and of significant biological importance since it 
affects the IL6 transcription (Curti et al., 2011). The frequencies of -174G>C variants were estimated to be 0.57 in 
Caucasians and 0.93 in Afro-Americans (Huang et al., 2007). Higher circulating IL6 levels have been associated with 
obesity and visceral fat deposition (Qi et al., 2007; Stephens et al., 2007), increased risk of impaired glucose tolerance, 
type 2 diabetes mellitus (T2DM) (Sattar et al., 2003), and high blood pressure (Fernandez-Real et al., 2001).   
PPARs modulate RAS by transcriptional control of all its components (Roszer and Ricote, 2010). Polymorphism in 
ACE and AT1R gene has been found significant for variability in many pathophysiological processes connected with 
RAS, including hypertension (Tiret et al., 1998), diabetes, and cardiovascular disease (Pujia et al., 1994). RAS might be 
involved in the pathophysiology of obesity (Engeli et al., 2000). The most common ACE gene polymorphism is the 
insertion/deletion (I/D) (rs4646994) of 287-bp Alu repeats located in intron 16.  
A nucleotide substitution (1166A>C) in 3′-UTR of the AT1R gene (rs1272176) results in increased expression of the 
receptor gene (Bonnardeaux et al., 1994). The increased frequency of the AT1R 1166C allele has been associated with 
essential hypertension (Tiret et al., 1998), cardiac hypertrophy (Pujia et al., 1994), myocardial infarction (Engeli et al., 
2000). But opposite findings have also been published where AT1R 1166CC genotype predisposes to favorable 
anthropometric and metabolic traits relative to cardiovascular risk (Möllsten et al., 2008). 
The influence of gene variants on phenotype expression seems to be population specific because of possible differences 
in environmental factors and genetic background (Groop, 2000).  
In this paper we consider the combined effects of PPARγ, LPL, IL6, ACE and AT1R that might confer a higher risk for 
MetSy or for some of its traits than individual gene variants in Croatian population.  
 
MATERIAL AND METHODS 
Subjects 
A total of 527 subjects (343 female, 184 male) of Croatian origin participated in the study, including 265 patients with 
MetSy and 262 controls (without MetSy criteria). Participants with MetSy were recruited among patients admitted to 
the University Hospital Center Zagreb, and control subjects were selected among hospital staff and other Zagreb 
citizens appointed for routine check up. The study was performed in the period between March 2010 and October 2012. 
MetSy was defined using the criteria established in the third report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and Treatment in Adults (NCEP-ATPIII, 2001). An individual with a 
combination of any three or more of the following risk factors was classified as having MetSy: waist circumference 
(WC), male >102 cm, female >88 cm; TG ≥1.7 mmol/L; HDL-C <1.0 in men and <1.3 mmol/L in women; systolic 
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blood pressure (SBP) or diastolic blood pressure (DBP) ≥ 130/85 mm Hg, or use of anti-hypertensive medications; and 
fasting blood glucose ≥ 6.1 mmol/L or use of antidiabetic medication with the age of diagnosis of T2DM ≥ 40 years. In 
the case of participants’ use of medications, corrections of medicated traits were made (Kraja et al., 2006). For control 
group we selected healthy subjects without MetSy and without any other serious illness. Data were collected on clinical 
variables including age, height, weight, and WC. Body mass index (BMI) was calculated as weight (kg)/height (m2). 
Participants with BMI between 25-30 kg/m2 were considered overweight, and those with BMI > 30 kg/m2 are obese. 
Blood samples for biochemical analyses (total cholesterol, TG, LDL-C, HDL-C and glucose) were collected after 
overnight fasting and were analyzed by using routine laboratory methods. All participants signed informed consent 
forms, and the study protocol was approved by Ethics Committee of the University Hospital Center Zagreb. 
 
Genotyping  
Genomic DNA was extracted from leukocytes using the salting out procedure (Miller et al., 1988), and genotyping of 
PPARγ Pro12Ala, LPL PvuII (-/+), IL6 -174G>C, ACE I/D and AT1R 1166A>C was performed according to previously 
published methods based on PCR or PCR-RFLP procedures (Oh et al., 2000; Xu et al., 2008; Jamie et al., 2005; Rigat et 
al., 1992; Hilgers et al., 1999, respectively). PCR amplifications were performed in 25 µL final volume in GeneAmp 
PCR System 9600 (Applied Biosystems, USA). 
 
Statistical analysis 
The level of statistical significance was set to 5% (p<0.05), and in all instances two-tailed tests of statistical significance 
were used. Means and standard deviations were used as measures of central tendency and variability for continuous 
variables, and independent samples t-test was used for their comparison. If variances were heterogeneous, t-test for 
unequal variances with corrected degrees of freedom was used. Univariate and multivariate prediction of MetSy, its 
traits and BMI was carried out by means of logistic regression, and odds ratios with 95% confidence intervals were 
given for each variable. To examine gene-gene interactions, total predictive model was built using hierarchical 
backward elimination approach (Kleinbaum and Klein, 2002), with initial model containing all variables and all 
possible pairs of gene-gene interactions. Interaction with the highest level of statistical significance from the full model 
was considered first so that logistic regression model without that interaction was compared to the model containing 
that interaction. If the difference between two models was not statistically significant, interaction was dropped out of 
the model and the procedure was repeated for the least significant interaction from the reduced model. If gene-gene 
interaction proved to be statistically significant, regression coefficients for each polymorphism et each of the categories 
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of the other one were examined by redefining their reference groups, since coefficients of variables in interaction are 
conditioned to the reference group of the other variable from that interaction (Jaccard, 2001). The analyses were carried 
out using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) statistical software package.  
 
RESULTS 
Baseline characteristics 
Baseline characteristics of study participants are given in Table 1. Patients had significantly higher BMI, WC, higher 
levels of TG, total cholesterol, LDL-C, glucose and significantly higher blood pressure and lower levels of HDL-C 
compared to controls (p<0.001). MetSy and control group did not differ significantly with respect to age and gender. 
 
Table 1. Baseline characteristics of study participants 
 Patients 
Mean +/- SD 
Controls 
Mean +/- SD 
P 
Age (yrs) 53.3 +/- 10.51 53.1 +/- 10.72 0.874 
Gender (N of male participants/All) 99/265 85/262 0.238 
Body mass index (kg/m2) 32.1 +/- 4.77 24.6 +/- 3.44 <0.001 
Waist circumference (cm) 107.3 +/- 11.15 85.1 +/- 11.42 <0.001 
Triglycerides (mmol/L) 2.82 +/- 2.21 1.21 +/- 0.73 <0.001 
Cholesterol (mmol/L) 6.0 +/- 1.11 5.5 +/- 1.02 <0.001 
High-density lipoprotein cholesterol (mmol/L) 1.22 +/- 0.33 1.69 +/- 0.41 <0.001 
Low-density lipoprotein cholesterol (mmol/L) 3.7 +/- 1.14 3.3 +/- 0.88 <0.001 
Glucose (mmol/L) 6.24 +/- 2.21 5.0 +/- 0.77 <0.001 
High Blood pressure (N of subjects with high BP/All) 235/260 71/255 <0.001 
Systolic blood pressure 152.4 +/- 26.0 124.8 +/- 14.24 <0.001 
Diastolic blood pressure 94.4 +/- 15.87 79.5 +/- 8.60 <0.001 
Differences between groups were evaluated by t-test, Mann-Whitney test or chi-square test depending on distribution normality. 
Significant values are indicated in bold. P<0.05 was considered statistically significant. 
 
 
Associations of PPARγ, LPL, IL6, ACE and AT1R gene variants with MetSy or its trait 
We found no differences in PPARγ Pro12Ala, LPL PvuII (-/+), IL6 174G>C, ACE I/D and AT1R 1166A>C genotype 
distributions between MetSy cases and controls (Table 2). We found no departure from the Hardy-Weinberg 
equilibrium. 
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Table 2. Genotype frequencies in case and control group 
Gene/Genotype 
Patients 
n(%) 
Controls 
n(%) 
OR (95% CI) 
ACE       
 DD 72 (27.2) 81 (30.9) 1  
 ID 132 (49.8) 130 (49.6) 1.14 (0.77-1.70) 
 II 61 (23.0) 51 (19.5) 1.35 (0.83-2.19) 
PPAR       
 Pro12Pro 200 (75.5) 199 (76.0) 1  
 Pro12Ala 62 (23.4) 60 (22.9) 1.03 (0.69-1.53) 
 Ala12Ala 3 (1.1) 3 (1.1) 1.03 (0.69-1.53) 
IL6       
 GG 85 (32.1) 91 (34.7) 1  
 GC 130 (49.1) 137 (52.3) 1.02 (0.69-1.49) 
 CC 50 (18.9) 34 (13.0) 1.57 (0.93-2.67) 
AT1R       
 AA 136 (51.3) 134 (51.1) 1  
 AC 114 (43.0) 110 (42.0) 1.02 (0.72-1.46) 
 CC 15 (5.7) 18 (6.9) 0.82 (0.40-1.70) 
LPL       
 -/- 62 (23.4) 71 (27.1) 1  
 -/+ 124 (46.8) 132 (50.4) 1.08 (0.71-1.64) 
 +/+ 79 (29.8) 59 (22.5) 1.53 (0.95-2.48) 
ABBREVIATIONS: OR = univariate odds ratio; 95% CI = 95% confidence interval for odds ratio 
 
 
When tested for the influence of interactions between PPARγ and its target genes LPL, IL6, ACE and AT1R on MetSy 
and its traits, separately in the group with and without MetSy, several statistically significant interactions were observed 
(Table 3). 
 
Table 3. Hierarchical backward elimination of gene-gene interactions  
 Least significant interaction / feature P (interaction) P (difference between models) 
Full model*    
Reduced model**    
 1 PPARγ x LPL PvuII / MetSy 0.008 0.007 
 2 PPARγ x ACE I/D / BMI 0.010 0.004 
    3 PPARγ x IL6 -174G>C / Glucose 0.001 <0.001 
ABBREVIATIONS: MetSy- metabolic syndrome, BMI-body mass index, p (interaction) = level of statistical significance for 
interaction, results of Wald χ2 test; p (difference between models) = level of statistical significance, comparison of model without 
interaction and model with interaction 
*Full model with all possible pairs of interactions included 
**Model from which interaction with highest level of statistical significance from previous model was excluded 
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Interaction of PPARγ and LPL and MetSy 
Interaction between PPARγ Pro12Ala and LPL PvuII (-/+) significantly improved prediction of MetSy, over and above 
prediction based on model containing no interactions (χ2=7.22; df=1; p=0.008) (Table 4).  
In the group of participants with LPL PvuII (-/-) genotype, participants with PPARγ Pro12Ala or Ala12Ala genotype 
had smaller odds for MetSy compared to those with Pro12Pro genotype (OR=0.12; 95% CI: 0.03-0.52, p=0.005). In the 
group of those participants with PPARγ Pro12Ala or Ala12Ala genotypes, those with LPL PvuII (-/+) or PvuII (+/+) 
genotype had greater odds for MetSy (OR=5.98; 95% CI: 1.46-24.47, p=0.013). 
In multivariate prediction, when adjusted for all other variables, age (p=0.012) and BMI (p<0.001) were also 
statistically significantly associated with MetSy. With each year increase in age, odds for MetSy decrease by 3% (OR = 
0.97; 95% CI = 1.54 – 1.85) and with each unit increase in BMI the odds for MetSy increase more than 1.5 times (OR = 
1.69; 95% CI = 1.54 – 1.85). 
 
Table 4. Total predictive model for MetSy with all polymorphisms 
 
Patients 
n(%) 
Controls 
n(%) 
ORmv (95% CI) P 
Age* 53.3 (10.51) 53.1 (10.72) 0.97 (0.94-0.99) 0.012 
Gender        
 female 166 (62.6) 177 (67.6) 1   
 male 99 (37.4) 85 (32.4) 1.27 (0.70-2.29) 0.427 
 total 265 (100.0) 262 (100.0)    
ACE        
 DD 72 (27.2) 81 (30.9) 1   
 ID or II 193 (72.8) 181 (69.1) 1.04 (0.56-1.92) 0.909 
 total 265 (100.0) 262 (100.0)    
PPARγ  if LPL Pvu (-/-)        
 Pro12Pro 50 (80.6) 52 (73.2) 1   
 Pro12Ala or Ala12Ala 12 (19.4) 19 (26.8) 0.12 (0.03-0.52) 0.005 
 total 62 (100.0) 71 (100.0)    
PPARγ  if LPL (-/+) or (+/+)        
 Pro12Pro 150 (73.9) 147 (77.0) 1   
 Pro12Ala or Ala12Ala 53 (26.1) 44 (23.0) 1.11 (0.54-2.25) 0.781 
 total 203 (100.0) 191 (100.0)    
IL6        
 GG 85 (32.1) 91 (34.7) 1   
 GC or CC 180 (67.9) 171 (65.3) 0.80 (0.45-1.44) 0.803 
 total 265 (100.0) 262 (100.0)    
AT1R        
 AA 136 (51.3) 134 (51.1) 1   
 AC or CC 129 (48.7) 128 (48.9) 0.69 (0.39-1.20) 0.185 
 total 265 (100.0) 262 (100.0)    
LPL PvuII  if PPARγ Pro12Pro        
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 (-/-) 50 (25.0) 52 (26.1) 1   
 (-/+) or (+/+) 150 (75.0) 147 (73.9) 0.67 (0.32-1.41) 0.290 
 total 200 (100.0) 199 (100.0)    
LPL PvuII if PPARγ Pro12Ala or             
                                 Ala12Ala 
       
 (-/-) 12 (18.5) 19 (30.2) 1   
 (-/+) or (+/+) 53 (81.5) 44 (69.8) 5.98 (1.46-24.47) 0.013 
 total  65 (100.0) 63 (100.0)    
BMI* 32.1 (4.77) 24.6 (3.44) 1.69 (1.54-1.85) <0.001 
Total cholesterol* 6.0 (1.11) 5.5 (1.02) 1.32 (0.82-1.12) 0.248 
LDL cholesterol* 3.7 (1.14) 3.3 (0.88) 1.41 (0.86-2.31) 0.170 
PPARγ x LPL     8.92 (1.77-44.88) 0.008 
ABBREVIATIONS: ORmv = multivariate odds ratio; 95% CI = 95% confidence interval for odds ratio; *Mean (standard deviation) 
Significant values are indicated in bold. P<0.05 was considered statistically significant. 
 
 
Interaction of PPARγ and IL6 and fasting blood glucose 
Interaction of PPARγ Pro12Ala and IL6 -174G>C statistically significantly improved prediction of high fasting blood 
glucose in the group of MetSy patients, over and above model containing no interactions (χ2=13.99; df=1; p=0.001). 
Inclusion of this interaction to the model containing no interactions increased Nagelkerke R square from 0.21 to 0.27 
(Table 5). In the group of patients with IL6 -174GG genotype, PPARγ Pro12Ala or Ala12Ala genotype carriers (taken 
together) had smaller odds of having high glucose compared to Pro12Pro genotype carriers (OR=0.10; 95% CI: 0.02-
0.57, p=0.01). In the group of patients with IL6 -174GC or CC genotype, PPARγ Pro12Ala or Ala12Ala genotype 
carriers (taken together) had larger odds of having high glucose compared to Pro12Pro genotype carriers (OR=2.39; 
95% CI: 1.11-5.17, p=0.026). In the group of patients with PPARγ Pro12Pro genotype, IL6 -174GC or CC genotype 
carriers (taken together) had smaller odds of having high glucose compared to IL-6 -174GG genotype carriers 
(OR=0.41; 95% CI: 0.20-0.83, p=0.013). In multivariate prediction, age (p=0.001), gender (p=0.045), and TGs 
(p=0.001) were also associated with high fasting blood glucose. With each year increase in age, odds for high glucose 
increase by 6% (OR = 1.06; 95% CI = 1.02 – 1.09), and male patients had more than two times larger odds of having 
high glucose (OR = 2.08; 95 % CI = 1.02 – 4.26). Each unit increase in TGs increases the odds for high glucose 1.3 
times (OR = 1.3; 95% CI = 1.11 – 1.53). 
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Table 5. Multivariate prediction of high fasting blood glucose in MetSy group 
 
High 
n(%) 
Normal 
n(%) 
ORmv (95% CI) P 
Age* 56.3 (9.25) 51.6 (10.87) 1.06 (1.02-1.09) 0.001 
Gender        
 female 52 (53.6) 113 (68.5) 1   
 male 45 (46.4) 52 (31.5) 2.08 (1.02-4.26) 0.045 
 total 97 (100.0) 165 (100.0)    
ACE        
 DD 24 (24.7) 47 (28.5) 1   
 ID or II 73 (75.3) 118 (71.5) 1.92 (0.95-3.89) 0.071 
 total 97 (100.0) 165 (100.0)    
PPARγ  if IL6 -174GG        
 Pro12Pro 33 (94.3) 35 (70.0) 1   
 Pro12Ala or Ala12Ala 2 (5.7) 15 (30.0) 0.10 (0.02-0.57) 0.010 
 total 35 (100.0) 50 (100.0)    
PPARγ  if IL6 -174GC/CC        
 Pro12Pro 39 (62.9) 90 (78.3) 1   
 Pro12Ala or Ala12Ala 23 (37.1) 25 (21.7) 2.39 (1.11-5.17) 0.026 
 total 62 (100.0) 115 (100.0)    
IL6  if PPARγ Pro12Pro        
 GG 33 (45.8) 35 (28.0) 1   
 GC or CC 39 (54.2) 90 (72.0) 0.41 (0.20-0.83) 0.013 
 total 72 (100.0) 125 (100.0)    
IL6  if PPARγ ProAla/AlaAla        
 GG 2 (8.0) 15 (37.5) 1   
 GC or CC 23 (92.0) 25 (62.5) 10.13 (1.66-61.89) 0.012 
 total 25 (100.0) 40 (100.0)    
AT1R A1166C        
 AA 49 (50.5) 86 (52.1) 1   
 AC or CC 48 (49.5) 79 (47.9) 0.96 (0.53-1.74) 0.893 
 total 97 (100.0) 165 (100.0)    
LPL PvuII        
 (-/-) 21 (21.6) 39 (23.6) 1   
 (-/+) or (+/+) 76 (78.4) 126 (76.4) 1.01 (0.49-2.05) 0.989 
 total 97 (100.0) 165 (100.0)    
BMI 32.3 (5.06) 32.1 (4.65) 1.01 (0.92-1.12) 0.781 
Total cholesterol 5.9 (1.05) 6.0 (1.14) 0.73 (0.56-1.12) 0.214 
LDL cholesterol 3.7 (1.01) 3.8 (1.22) 1.14 (0.84-1.55) 0.400 
Waist circumference 108.7 (11.11) 106.4 (11.07) 1.01 (0.97-1.06) 0.615 
Triglycerides 3.1 (2.97) 2.7 (1.60) 1.30 (1.11-1.53) 0.001 
HDL cholesterol  1.3 (0.37) 1.2 (0.31) 3.60 (0.91-2.23) 0.101 
Systolic blood pressure 156.5 (28.40) 150.3 (24.32) 1.02 (1.00-1.03) 0.120 
Diastolic blood pressure 95.1 (16.01) 94.3 (15.65) 0.98 (0.95-1.02) 0.330 
PPARγ x IL6     24.81 (3.49-176.38) 0.001 
ABBREVIATIONS: ORmv = multivariate odds ratio; 95% CI = 95% confidence interval for odds ratio; *Mean (standard deviation) 
Significant values are indicated in bold. P<0.05 was considered statistically significant. 
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Interaction of PPARγ and ACE and obesity 
PPARγ Pro12Ala and ACE I/D gene interaction statistically significantly improved prediction of obesity in the group of 
MetSy patients, over and above prediction based on model containing no interactions (χ2=8.08; df=1; p=0.004). 
Inclusion of this interaction to the model containing no interactions increased Nagelkerke R square from 0.51 to 0.53 
(Table 6). In the group of patients with PPARγ Pro12Ala or Ala12Ala genotype, patients with ACE ID or II genotype 
had 89% smaller odds for obesity compared to those with DD genotype (OR=0.11; 95% CI: 0.01-0.88, p=0.038). In the 
group of those patients with ACE DD genotype, those with PPARγ Pro12Ala or Ala12Ala genotype had about ten times 
greater odds for obesity (OR=9.98; 95% CI: 1.18-84.14, p=0.034).   
In multivariate prediction, gender (p=0.009), WC (p<0.001), and HDL-C (p=0.043) were also associated with obesity. 
Male patients had smaller odds for obesity (OR = 0.30; 95% CI = 0.12 – 0.74). With each unit increase in WC the odds 
for obesity increase 1.26 times (OR = 1.26; 95% CI = 1.18 – 1.34), and with each unit increase in HDL-C the odds for 
obesity decrease 76% (OR = 0.24; 95% = 0.06 – 0.96). 
 
Table 6. Multivariate prediction of obesity in MetSy group  
 Yes No ORmv (95% CI) P 
Age* 53.1 (9.97) 53.7 (11.57) 0.99 (0.96-1.03) 0.582 
Gender        
 female 104 (59.8) 61 (67.8) 1   
 male 70 (40.2) 29 (32.2) 0.30 (0.12-0.74) 0.009 
 total 174 (100.0) 90 (100.0)    
ACE  if PPARγ Pro12Pro        
 DD 32 (24.6) 20 (29.0) 1   
 ID or II 98 (75.4) 49 (71.0) 2.36 (0.93-6.01) 0.072 
 total 130 (100.0) 69 (100.0)    
ACE  if PPARγ Pro12Ala/Ala12Ala        
 DD 18 (40.9) 2 (9.5) 1   
 ID or II 26 (59.1) 19 (90.5) 0.11 (0.01-0.88) 0.038 
 total 44 (100.0) 21 (100.0)    
PPARγ  if ACE DD        
 Pro12Pro 32 (64.0) 20 (90.9) 1   
 Pro12Ala or Ala12Ala 18 (36.0) 2 (9.1) 9.98 (1.18-84.14) 0.034 
 total 50 (100.0) 22 (100.0)    
PPARγ  if ACE ID/DD        
 Pro12Pro 98 (79.0) 49 (72.1) 1   
 Pro12Ala or Ala12Ala 26 (21.0) 19 (27.9) 0.44 (0.17-1.15) 0.094 
 total 124 (100.0) 68 (100.0)    
IL6        
 GG 51 (29.3) 33 (36.7) 1   
 GC or CC 123 (70.7) 57 (63.3) 1.16 (0.55-2.46) 0.698 
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 total 174 (100.0) 90 (100.0)    
AT1R        
 AA 90 (51.7) 45 (50.0) 1   
 AC or CC 84 (48.3) 45 (50.0) 1.14 (0.56-2.31) 0.722 
 total 174 (100.0) 90 (100.0)    
LPL PvuII        
 (-/-) 43 (24.7) 18 (20.0) 1   
 (-/+) or (+/+) 131 (75.3) 72 (80.0) 0.77 (0.33-1.81) 0.550 
 total 174 (100.0) 90 (100.0)    
Total cholesterol* 5.9 (1.11) 6.1 (1.12) 0.91 (0.49-1.70) 0.777 
LDL cholesterol* 3.7 (1.15) 3.8 (1.13) 0.93 (0.50-1.74) 0.813 
Waist circumference* 111.7 (10.44) 98.9 (6.83) 1.26 (1.18-1.34) <0.001 
Triglycerides* 2.91 (2.27) 2.6 (2.12) 1.04 (0.83-1.30) 0.730 
HDL cholesterol* 1.2 (0.32) 1.3 (0.36) 0.24 (0.06-0.96) 0.043 
Systolic blood pressure* 153.7 (26.50) 149.7 (25.13) 1.02 (0.99-1.04) 0.197 
Diastolic blood pressure* 94.8 (15.09) 93.2 (17.17) 0.99 (0.96-1.03) 0.719 
Fasting blood glucose* 6.3 (2.28) 6.1 (2.09) 0.90 (0.73-1.11) 0.309 
PPARγ x ACE I/D     0.04 (0.004-0.47) 0.010 
ABBREVIATIONS: ORmv = multivariate odds ratio; 95% CI = 95% confidence interval for odds ratio; *Mean (standard deviation) 
Significant values are indicated in bold. P<0.05 was considered statistically significant. 
 
 
Single gene correlations in the control group 
1. In multivariate prediction PPARγ Pro12Ala or Ala12Ala genotype carriers had almost four times larger odds of 
having high WC compared to those with PPARγ Pro12Pro genotype carriers (OR=3.86; 95% CI: 1.24-12.06; p = 0.020) 
(Table 7). 
2. In multivariate prediction AT1R 1166AC or CC genotype carriers had about eight times larger odds of having high 
TGs compared to AT1R AA genotype carriers (OR=8.05; 95% CI: 1.85-35.0; p = 0.005). 
 
Table 7. Associations of single gene variants in the control group  
Feature Genotype 
High 
n (%) 
Normal 
n (%) 
ORmv (95% CI) P 
Waist 
circumference 
PPARγ Pro12Ala        
 Pro12Pro 27 (65.9) 142 (77.2) 1  
 Pro12Ala/Ala12Ala 14 (34.1) 42 (22.8) 3.86 (1.24-12.06) 0.020 
 
Triglycerides 
 
AT1R 1166A>C 
       
 AA 8 (26.7) 112 (53.1) 1  
 AC or CC 22 (73.3) 99 (46.9) 8.05 (1.85-35.0) 0.005 
 total 30 (100.0) 211 (100.0)     
ABBREVIATIONS: ORmv = multivariate odds ratio; 95% CI = 95% confidence interval for odds ratio 
Significant values are indicated in bold. P<0.05 was considered statistically significant. 
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DISCUSSION 
Assuming a modest role of single polymorphisms as markers of complex traits and diseases, the study of variant gene 
combinations could provide complementary information that could be clinically important. The obtained results 
confirmed the significance of the interacting effects of the PPARγ polymorphisms with some of its target genes.  
Although PPARγ Pro12Ala variant in this study showed no influence on MetSy when tested separately, its interaction 
with LPL PvuII (-/+) variants seems to be relevant. Carriers of low activity alleles, PPARγ Ala and LPL PvuII (+), had 
six times greater odds for MetSy. The PPARs have been implicated in the regulation of adipocyte differentiation and 
lipid and fatty acid metabolism. As both central obesity and serum lipids were found to be related with LPL activity, it 
is reasonable to assume that those two gene interactions contribute to the development of MetSy. Considering 
transcriptional regulation, the activity of the LPL promoter has been studied extensively. The 5' regulatory region 
contains a large number of specific cis-acting elements, among others the PPAR response element (Schoonjans et al., 
1996). Because the LPL promoter was shown to be ~ 30% less efficiently transactivated in the presence of the PPARγ 
Ala allele in a study in vitro, Schneider group proved that the Pro12Ala substitution may lead to decreased LPL activity 
in vivo (Schneider et al, 2002).  
Our results further pointed to the importance of the interacting role of the PPARγ with target gene IL6 influencing the 
glucose level. The role of PPARs has been confirmed in glucose homeostasis but with different results. When analyzed 
as a single marker for T2DM risk, PPARγ Ala variant was considered protective in different studies (Gouda et al., 
2010). However, for association between PPARγ and T2DM, environmental factors as dietary lipids (Scacchi et al., 
2007) and even intrauterine condition (de Rooij et al., 2006) were pointed to be relevant in addition to gene variants. In 
our study PPARγ Ala variant was found protective in patients with IL6 -174GG genotype, while in the case of IL6 -
174C allele carriers, PPARγ Ala12 variant lost its protective role, and Ala12 carriers had even larger odds for high 
glucose levels compared to Pro12 variant. In Asian Indian population PPARγ Ala12Ala genotype was associated with 
obesity and insulin resistance (Bhatt et al., 2012), indicating that ethnicity with different genetic and environmental 
background can have dominant role. For Croatian population, multivariate prediction revealed that cholesterol and TGs 
were also associated with high fasting blood glucose, where each unit increase in TGs increased the odds for high 
glucose 1.3 times. The relationship between insulin resistance and metabolic risk factors is complex and abdominal 
obesity with dysfunctional adipose tissue might be one of risk predispositions. Variants of IL6 gene -174G>C are 
associated with cytokine and metabolic modulation that can lead to impaired glucose and lipid homeostasis and 
increased metabolic risk. Association of the C allele with obesity has been documented (Berthier et al., 2003). Due to 
lower energy expenditure and insulin sensitivity, carriers of the CC genotype could be more prone to insulin resistance 
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and obesity (Fernandez-Real et al., 2000; Kubaszek et al., 2003). Our results are in accordance to such published data. 
Again, other opposite results can be found in the literature. It has been found that IL6 -174C allele carriers had 
significantly lower fasting glucose (Hutch et al., 2009). In our study, association between IL6 -174CC genotype and 
higher WC was observed in the control group, which is in accordance with published data and points to the association 
between C allele and obesity (Berthier et al., 2003). Further, we found interactions of PPARγ and ACE genotypes 
significant for BMI, specifically in the group of patients with ACE DD genotype where PPARγ Ala allele carriers had 
greater odds for obesity, which is in accordance with the data from previous studies (Passaro et al., 2011) in which have 
also been reported ACE DD / PPARγ Ala female carriers having a higher BMI and fat distribution, but not MetSy. 
Association of the ACE DD genotype with BMI can be explained by the observation that ACE DD subjects have 
increased levels of plasma ACE (Rigat et al., 1990; Tiret et al., 1992), and therefore potentially increased level of 
angiotensin II which is considered a trophic factor in the differentiation of preadipocytes to mature adipocytes (Saint-
Marc et al., 2001). Previously published data also suggest that the RAS might be involved in the pathophysiology of 
obesity (Engeli et al., 2000). The data on the influence of PPARγ 12Ala variant on BMI are inconsistent, being 
associated with decreased BMI (Deeb et al., 1998; Damcott et al., 2004) or increased BMI (Masud and Ye, 2003), and 
increased risk of obesity (Ochoa et al., 2004). In our study, it was observed for the control group in multivariate 
prediction, that PPARγ 12Ala allele carriers had larger odds of having high WC compared to those with PPARγ Pro12 
allele carriers.   
Presented data confirmed that PPARγ gene variants, interacting with some of its polymorphic target genes, can 
modulate pathophysiological processes in the development of MetSy in Croatian population. We have also confirmed 
that between-study heterogeneity can be at least partly attributed to ethnicity and gene-gene interactions. 
 
Study Limitations 
The size of our population might be a limitation. Another limitation might be that the effects of environmental factors 
and controlling the risk of obesity and MetSy were not evaluated in this study.  
Although further studies are needed to confirm our results, the interplay between genes seems to be significant.  
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